524516 — Bacil Pharma Income Statement
0.000.00%
Last trade - 00:00- IN₹232.54m
- IN₹205.60m
- 18
- 22
- 54
- 19
Annual income statement for Bacil Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0 | 0 | 0 | — |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.71 | 1.59 | 1.81 | 1.89 | 2.54 |
| Operating Profit | -1.71 | -1.59 | -1.81 | -1.89 | -2.54 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.4 | -38.6 | -1.02 | -0.59 | 4.08 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.39 | -38.6 | -1.02 | -0.591 | 4.04 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.39 | -38.6 | -1.02 | -0.591 | 4.04 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.39 | -38.6 | -1.02 | -0.591 | 4.04 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.41 | -2.47 | -0.17 | -0.1 | 0.64 |